Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for EBV Prevention in Pediatric Allogeneic HSCT
NCT07693881Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in Epstein-Barr virus infection (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Incidence of Epstein-Barr virus (EBV) infection at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
rituximab
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07693881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693881.